Can Insulin Degludec Reduce Ketoacidosis Rates? Exciting New Data Suggests “Maybe”.

Andrew Norris, MD PhDPost by
Andrew Norris, MD PhD
Director, Pediatric Endocrinology & Diabetes
University of Iowa Stead Family Children’s Hospital

Diabetic ketoacidosis (DKA) is a diabetes emergency that can result in death when not detected quickly and treated in a timely fashion.  DKA is most commonly caused by taking insufficient insulin, especially forgetting to take long acting insulin, or taking insufficient extra insulin during illness. Children and adolescents with diabetes are at particular risk to develop DKA. For reasons that are not fully understood, rates of DKA are increasing (see this 2018 commentary in Diabetes Care). Insulin degludec is an ultra-long-acting insulin analog. Its duration of action exceeds 30 hours, which is longer than other current long acting insulin types.  For this reason, it has been postulated that use of insulin degludec might reduce DKA risk when compared to other long-acting insulin analogs, especially among those who occasionally forget to take their long acting insulin. However, evidence has mixed. A study in 2015 Pediatric Diabetes found a reduction in ketosis when comparing children on degludec versus insulin detemir (note: the study was funded by Novo Nordisk, the maker of both degludec and detemir).  This is the least meaningful of all possible comparisons since insulin detemir is the shortest acting of current long acting insulins. This 2015 European regulatory document presents an analysis of DKA rates from a company trial comparing insulin degludec versus detemir, finding no differences. A study published in 2018 Diabetes Therapy examined 42 adults who switched to insulin degludec found fewer DKA events after the switch, though the study was not powered for statistical conclusions (again this study was funded by Novo Nordisk). This month, work published in Feb 2020 Hormone Research in Paediatrics reports a retrospective study of 35 adolescents with DKA who switched from insulin glargine (in its most common “U100” formulation) to insulin degludec. The adolescents experienced significantly fewer DKA episodes after the switch. This exciting data suggests that degludec may indeed help reduce risks of DKA in youth at risk.  Although these are encouraging, the retrospective nature of the study and lack of a control group prevents firm conclusions. In general, DKA rates are expected to subside with time in adolescents as they mature and better learn to prevent this unpleasant complication. A control group of adolescents who did not switch to degludec would have helped interpret the results. Degludec has other benefits, especially less hypoglycemia compared to other long acting insulins (see this 2018 meta-analysis).

Watching the Brain Think: Finding Differences Between Children with and without Type 1 Diabetes

with the advent of techniques to strengthen brain regions, such as transcranial magnetic stimulation, might this type of research help guide possible interventions?” –Andrew Norris

Dr. Tsalikian

Dr. Tsalikian and collaborators across the country have been studying brain cognitive function in children with and without type 1 diabetes. In a study just published in PLOS Medicine, they report interesting differences. They used functional magnetic imaging resonance (fMRI) to measure activation in various brain locations while the children were given tasks. Compared to children without diabetes, those with type 1 diabetes exhibited two differences. One of the observed changes was impaired control of a region towards the back of the brain and this impairment typically leads to diminished task performance. In contrast, there was enhanced activation of a region towards the front of the brain involved in executive control. It appears that these two changes balanced each other, in that the two groups had similar task performance. Simply put, it appears that the brains of children with type 1 diabetes are able to compensate for impairments presumably induced by long-term exposure to high blood sugars. More study is needed to understand this latter point in particular, for example would the pattern normalize if the blood sugars were held to the normal range during the study? Furthermore, more study is needed to understand the broader implications of this work, for example might these or related changes contribute to the increased risk of depression in persons with diabetes? Finally, with the advent of techniques to strengthen brain regions, such as transcranial magnetic stimulation, might this type of research help delineate important interventions? Also involved in the study from our Division were Dr. Tansey, Julie Coffey, Joanne Cabbage, Sara Salamati, and Rachel Bisbee.

A Lower Safe Threshold for Treating Hypoglycemia in Newborns? An Endocrine Perspective.

Andrew Norris, MD PhDPost by
Andrew Norris, MD PhD
Director, Pediatric Endocrinology & Diabetes
University of Iowa Stead Family Children’s Hospital

There has long been some controversy regarding what blood glucose threshold should be used in newborns to guide when to initiate therapeutic intervention. This is an important concern, because sufficiently severe hypoglycemia can cause damage to the brain. However, it has been difficult to ascertain what degrees of hypoglycemia induce risk. This week the New England Journal of Medicine has published results from a new study focused on this question. Infants were randomized to receive intervention once blood glucose was under 47 (conventional cutoff) or 36 mg/dL. Psychomotor development was assessed at 18 months of age. The study found that outcomes in the more liberal cutoff group (36 mg/dL) were not any different from the conventional group. This suggests that the more liberal cutoff may be reasonable to use in clinical practice. An important caveat from the perspective of pediatric endocrinology is that this study pertains to healthy infants who do not have any specific endocrinologic or metabolic disorder. In fact the authors “emphasize the need for a higher target glucose concentration in newborns who have persistent hypoglycemia due to endocrine or metabolic disorders“. –Andrew Norris

Impaired Glucagon Responses in Patients with Cystic Fibrosis and Hypoglycemia

“Thus, these data implicate that cystic fibrosis induces defects in glucagon secretion leading to hypoglycemia risk. The association with pancreatic insufficiency suggests a link to pancreatic exocrine disease.” –Andrew Norris

Andrew Norris, MD PhDPost by
Andrew Norris, MD PhD
Director, Pediatric Endocrinology & Diabetes
University of Iowa Stead Family Children’s Hospital

Results from an important recent clinical study of hypoglycemia in patients with cystic fibrosis (CF) are now available. The study was conducted at the University of Washington and headed by preeminent diabetes physiologist Dr. Steven Kahn. Non-diabetic adults with cystic fibrosis were challenged with a 3-hour 75-gram frequently-sampled oral glucose tolerance test.

Half (14/27) of the subjects experienced hypoglycemia during the test. The glycemic pattern during the test was similar between these two groups until 135 minutes and thereafter, when the hypoglycemia group diverged downward. Those who exhibited hypoglycemia were more likely to be pancreatic insufficient. Importantly, those with hypoglycemia had lower plasma insulin & C-peptide levels. Modeling suggest that insulin sensitivity was greater in the subjects with hypoglycemia, accounting for the lower insulin levels. Importantly though, the “oral disposition index” did not differ between the two groups. This indicates that the amount of insulin secreted between the two groups would expected to have the same actions on lowering glucose when accounting for insulin sensitivity. Perhaps one could argue that the “oral disposition index” should have been lower in the hypoglycemia group, but in fact there was a trend towards lower values in this group (P=0.16). Plasma GLP-1 and GIP did not differ between the groups. In the hypoglycemia group, plasma epinephrine rose in the hypoglycemia group, albeit modestly. Cortisol did not rise, though it is not clear how many patients reached the lower blood glucose thresholds needed to trigger cortisol secretion. Growth hormone rose in some but not all patients. Perhaps most importantly, glucagon did not rise with hypoglycemia and did not differ at any point between the two groups.

These results suggest an impairment in counterregulatory response in patients with CF and hypoglycemia. Typically, the threshold for glucagon secretion occurs at less severe degrees of hypoglycemia than for other counterregulatory responses (see this nice review from Elizabeth Seaquist). Furthermore, the hypoglycemia in these subjects was mild. Thus, these data implicate that cystic fibrosis induces defects in glucagon secretion leading to hypoglycemia risk. The association with pancreatic insufficiency suggests a link to pancreatic exocrine disease. However, the mechanisms responsible remain to be determined. The manuscript describing these results is now published in the prestigious journal Diabetologia (link to article).

Senior Endocrine Fellow Publishes Research Discovering Genes that may Modify 22q11.2 Deletion Syndrome.

Dr. Pinnaro

Dr. Pinnaro, pediatric endocrine fellow, has published her recent research that finds several candidate genes which may modify the phenotype of 22q11.2 syndrome. This genetic syndrome can cause congenital structural heart disease, failure of the parathyroid glands to properly form, and immunodeficiency. Although the effects of the syndrome vary from person to person, the reasons for this variability is unknown. Thus, Dr. Pinnaro set out to understand whether other genetic regions might be the reason. Her findings show that various genes might indeed contribute. She is the lead author on the work which is published in the January 2020 issue of Molecular Genetics & Genomic Medicine. Congratulations to Dr. Pinnaro for the results of her hard work in this area.

Might Continuous Glucose Monitoring Discern Diabetes Pathogenesis?

Andrew Norris, MD PhDPost by
Andrew Norris, MD PhD
Director, Pediatric Endocrinology & Diabetes
University of Iowa Stead Family Children’s Hospital

It can be challenging to distinguish type 1 from type 2 diabetes, especially in overweight adolescents and other populations. An upcoming report in the scientific journal Diabetes Care (link here) presents provocative data suggesting that continuous glucose monitoring (CGM) may distinguish forms of diabetes that occur because of loss of insulin secretion capacity (such as type 1) from forms due to insulin resistance (type 2). In particular, when CGM was performed when diabetes was very mild, insulin secretion defects were marked by increased blood glucose variability but normal fasting glucoses, whereas insulin resistance was marked by an overall increase in baseline (i.e. fasting) blood glucose levels.

–Andrew Norris

Endocrine Care of Children with Neuromuscular Disorders

Dr. Curtis

Children, adolescents, and young adults with neuromuscular disorders are at risk for various endocrine complications. For example, Duchenne muscular dystrophy is associated with risk of various endocrine conditions including poor bone health, adrenal insufficiency, obesity, pubertal delay, and short stature. To help with these issues, in 2019, Dr. Vanessa Curtis joined the multidisciplinary Neuromuscular team at the University of Iowa to provide endocrine care to patients in this clinic. This week, Dr. Curtis attended the Parent Project MD meeting in San Diego to further her skills in this emerging area of medicine.

Endocrine Conditions that “Break the Rules”

Andrew Norris, MD PhDPost by
Andrew Norris, MD PhD
Director, Pediatric Endocrinology & Diabetes
University of Iowa Stead Family Children’s Hospital

In pediatrics and medicine we are taught various rules that help us interrogate a person’s health . However, there are a variety of endocrine  disorders that alter normal physiology such that the usual rules no longer apply. Failure to recognize this can lead to erroneous interpretation of a person’s condition, sometimes with even fatal results


“Good urine output indicates that a child is well hydrated”

This is a stalwart rule in pediatrics. When a child is making plenty of urine, this proves that the child is well hydrated. In general this is sage advice, but there are important endocrine exceptions:.

  • Hyperglycemia / diabetes mellitus: When a child’s blood sugar is elevated, this produces an obligate osmotic diuresis. As a result, urine output remains brisk even when the child has become significantly dehydrated. To further exacerbate this, hyperglycemia leads to an osmotic fluid shift from the interstitium to the intravascular compartment, further increasing renal fluid output at the expense of worsening whole body hydration status. For these reasons, the child presenting with severe hyperglycemia is typically more dehydrated than the history and physical examination would suggest. There are cases where clinicians have been falsely reassured by a vomiting child’s brisk urine output, concluding that everything is fine when the child truly has severe hyperglycemia, with sometimes fatal consequences. Pediatricians in training are advised to become practiced and adept at asking children and families about any changes in thirst and urination, as this can be a fairly effective screening tool to assess for out-of-control undiagnosed severe diabetes.
  • Diabetes insipidus: In the child who has diabetes insipidus, urine output is not a reliable indicator of hydration status. When diabetes insipidus is not treated, brisk urine output occurs even in the face of dehydration. When diabetes insipidus is treated with vasopressin or DDAVP, urine output diminishes when the medication is active, even when hydration status is excellent.

“Children and adolescents can tolerate the physical stress of fever or vomiting.”

Typically, children can tolerate common physiological stressors such as significant febrile illness or vomiting / fasting during gastroenteritis. However, often children with underlying medical conditions do not tolerate such physiological stressors as well. Included in such underlying illnesses are several important and relatively common endocrine conditions

  • Adrenal insufficiency: An important component of the response to physiologic stress is increased secretion of adrenal hormones, especially cortisol. Children who are unable to secrete adequate amounts of cortisol can experience hypoglycemia, hyponatremia, and sometimes even cardiovascular collapse in response to physiologic stressors that ordinarily a child could tolerate without difficulty. Conditions in which cortisol secretion in response to stress can be impaired include panhypopituitarism, central adrenal insufficiency, congenital adrenal hyperplasia, Addison’s disease, iatrogenic adrenal suppression, and any form of hypoadrenalism. Children who have impaired mineralocorticoid secretion are at even greater risk for electrolyte imbalance, specifically hyponatremia and hyperkalemia, and cardiovascular collapse. common causes of mineralocorticoid deficiency include congenital adrenal hyperplasia and Addison’s disease. Fortunately stress dose hydrocortisone is an effective means to treat children with these conditions and enable them to better tolerate physiologic stressors.
  • Diabetes mellitus: Pediatric patients with diabetes require special attention to blood glucose and Insulin management during times of physiological stress. During such times, especially in patients with type 1 diabetes, there will be an increased risk of dysglycemia, ketones, dehydration, and diabetic ketoacidosis.
  • Hyperthyroidism: Patients who have active hyperthyroidism can experience significant deterioration during physiological stress and illness. In some cases, illness can precipitate thyroid storm, which can include life-threatening hyperthermia, confusion, diarrhea, tachycardia, arrhythmia, cardiovascular collapse, and coma.

“Children and adolescents tolerate exercise well”

In general children and adolescents can exercise seemingly ad infinitum. however there are a number of medical exceptions to this, including situations in which it is not entirely safe for a child to exercise vigorously. Several endocrine conditions are included among these exceptions to this common rule.

  • Hyperthyroidism: Children and adolescents with active hyperthyroidism typically experience a degree of exercise intolerance. If the hyperthyroidism is significant, some patients will even experience cardiovascular decompensation and/or hyperthermia triggered by vigorous exercise.
  • Ketonemia: children with diabetes can benefit greatly from exercise. however, when diabetes and ketones are present, exercise can exacerbate the degree of ketonemia, and in extreme cases can contribute to the development of diabetic ketoacidosis. standard advice during ketonemia in pediatric patients with diabetes is to administer supplemental insulin, optimize hydration, and delay a vigorous exercise until after the ketones have been cleared.

“Children do not experience electrolyte problems as long as renal function is normal and fluid / electrolyte intake is adequate.”

Although adequate fluid and electrolyte intake coupled with normal renal function is typically sufficient to maintain normal electrolyte balance, there are important exceptions to this rule especially in the endocrine system.

  • Diabetes insipidus: Patients with untreated diabetes insipidus generally develop hypernatremia during normal intakes of fluid and electrolytes. provision of greater than normal amounts of free water and or medical treatment of the diabetes insipidus is required to prevent hypernatremia.
  • SIADH (syndrome of inappropriate ADH secretion): Patients with SIADH have a tendency towards hyponatremia when provided normal amounts of fluid and electrolyte. Fluid restriction is commonly used to prevent hyponatremia in such patients.
  • Mineralocorticoid deficiency: Patients with untreated mineralocorticoid deficiency are prone to hyponatremia and hyperkalemia despite normal fluid and electrolyte intake. Common pediatric causes of mineralocorticoid deficiency include congenital adrenal hyperplasia and Addison’s disease.

“Failure of an infant to gain weight is a feeding issue.”

Many times, when an infant is not adequately gaining weight this can indicate various feeding issues. However, there are many medical diseases which can cause poor weight gain during infancy for reasons other than poor nutritional intake. There are several important to endocrine diseases among these conditions. Congenital adrenal hyperplasia typically causes poor weight gain and failure to thrive beginning towards the end of the first week of life. Neonatal Graves disease, when severe, presents with failure of a newborn to gain weight typically in the first week or two of life. Neonatal diabetes mellitus can present at various times in the first six months of life and can lead to poor weight gain.

Dr. Pesce to Lead National Endocrine Learning Committee

Dr. Pesce

We are pleased to report that Dr. Liuska Pesce, one of our pediatric endocrine faculty, has been selected to co-chair & then chair the Pediatric Endocrinology Self-assessment Program for the Endocrine Society in 2020 & 2021. As part of this group, she helped publish Pediatric ESAP 2019-2020, ESAP Special Edition: Historical Perspectives for Today’s Clinician, and Pediatric ESAP 2017-   2018.

Dr. Larson Ode Publishes on the Endocrine Complications of Cystic Fibrosis.

Dr. Larson Ode

It has been a productive fall for Dr. Larson Ode, who has published 5 review articles focused on various endocrine complications of cystic fibrosis. You can find summaries of these works at the following links: onetwothreefourfive. Dr. Larson Ode is a leading expert in the clinical care and clinical research involving persons with cystic fibrosis who have developed diabetes and other endocrine complications. She sees children and adult patients in the cystic fibrosis clinic to help them manage these conditions. On the research side, she coordinates a variety of clinical studies here at Iowa and also at other academic medical centers across the country to better understand these complications. She is also serving as a career and research mentor to several junior endocrinology faculty across the country to further their expertise and research in this important area. Kudos Dr. Larson Ode on your accomplishments!